Multiple deadlocks in the development of nonprofit drugsArticle Published on 2022-09-012022-10-04 Journal: Drug discovery today [Category] 신약개발, [키워드] addressed administer biomedicine Cancer clinical clinical trial clinical trials Community country COVID-19 COVID-19 pandemic Dexamethasone disulfiram drug drugs effort Healthcare system identify Multiple Nonprofit drugs Nonprofit drugs. organized pandemic recovery Research shown [DOI] 10.1016/j.drudis.2022.06.001 PMC 바로가기 [Article Type] Article
Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant casesResearch article Published on 2022-09-012022-10-05 Journal: Annals of Medicine and Surgery [Category] 진단, 치료제, [키워드] assessment Combined complete recovery corticosteroid therapy COVID 19 COVID-19 Dexamethasone disease Efficacy evaluate hearing loss injection Labyrinthitis management objective oral steroid outcome Patient patients Prednisolone Result systemic corticosteroid treated Treatment vestibular disorder was done with COVID-19 [DOI] 10.1016/j.amsu.2022.104429 [Article Type] Research article
High-Dose versus Low-Dose Corticosteroids in COVID-19 Patients: a Systematic Review and Meta-analysisResearch article Published on 2022-09-012022-10-05 Journal: Journal of cardiothoracic and vascular anesthesia [Category] COVID19(2023년), SARS, 비임상, 임상, [키워드] Admission Analysis certainty of evidence Clinical efficacy coronavirus Corticosteroid Corticosteroids COVID-19 COVID-19 patients demonstrated Dexamethasone did not reduce dose evaluate Evidence group heterogeneity High-dose higher risk Hospital stay hyperglycemia ICU IMPROVE incidence Inconclusive infection rate intensive care low-dose corticosteroid low-dose corticosteroids measurement mechanical ventilation Meta-analysis Methylprednisolone mortality rate no significant difference objective observational study participant patients positive randomized clinical trial Randomized controlled trial Respiratory Support Result review SARS-CoV-2 SARS-CoV-2 PCR setting significant difference systematic review Trial trial sequential analysis [DOI] 10.1053/j.jvca.2022.05.011 [Article Type] Research article
Impacts of the COVID-19 pandemic on pharmaceuticals in wastewater treated for beneficial reuse: Two case studies in central PennsylvaniaArticle Published on 2022-09-012022-11-16 Journal: Journal of environmental quality [Category] 치료기술, [키워드] acute respiratory syndrome affected analyzed Antibiotics Area authority calculated collected Concentration concentrations connection coronavirus COVID-19 pandemic Dexamethasone doxycycline effective explained facility FIVE Health highlight hospitalized patient Hydroxychloroquine Impact Medicine no correlation occurred pandemic patients with COVID-19 persistence plant plants powerful tool Quotient Reclamation Remdesivir returned reuse risk Sample state Surveillance therapeutic agent treated Treatment university utility Variation virus water with COVID-19 would increase [DOI] 10.1002/jeq2.20398 PMC 바로가기
Comparison of the effect of intravenous dexamethasone and methylprednisolone on the treatment of hospitalized patients with COVID-19: a randomized clinical trialRandomized Controlled Trial Published on 2022-09-012022-10-04 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 바이오마커, 임상, 치료법, [키워드] addition Admission age analysis of variance analyzed assigned confidence interval COVID-19 Dexamethasone doses duration of hospitalization Effect Effectiveness enrolled Hospital stay Hospitalization hospitalized patient hyperglycemia hypokalemia Inpatient intensive care intravenous leukocyte Lymphocyte count Methylprednisolone methylprednisolone group moderate Mortality mortality rate Oxygen therapy Patient Primary outcome protocol randomized clinical trial Randomly Result secondary outcome severe COVID-19 significantly SPSS statistically significant t-test therapeutic Treatment two group with COVID-19 [DOI] 10.1016/j.ijid.2022.07.019 PMC 바로가기 [Article Type] Randomized Controlled Trial
In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivirResearch article Published on 2022-09-012022-10-05 Journal: Chemico-biological interactions [Category] 변종, 치료제, [키워드] Activation analyzed Anti-inflammatory drugs Antibiotics Antiviral appear AUC cannabidiol carboxylesterase 1 carrier CES1 clearance clinical study COVID-19 Dexamethasone enzyme evaluate evaluated fraction G143E hospitalized patient hydrolysis Hydroxychloroquine impairment in vitro in vitro study in vivo indicated individual inhibit inhibitor Interaction Ivermectin mechanism medication metabolism nine partial inhibition pharmacokinetic polymorphism produced RDV recent reduction Remdesivir required substrates suggested therapeutic agent treating COVID-19 Treatment unlikely variant with COVID-19 [DOI] 10.1016/j.cbi.2022.110097 [Article Type] Research article
Inflammatory and thrombotic parameters associated with the COVID-19 course in Poland (SARSTer study)Article Published on 2022-09-012022-11-15 Journal: Advances in medical sciences [Category] 바이오마커, [키워드] analyzed Anticoagulants C-reactive protein clinical Clinical improvement Coagulation Concentration Course COVID-19 CRP D-dimer database Dexamethasone diagnosed with COVID-19 epidemiologist examined ferritin group IL-6 Inflammatory marker interleukin-6 Laboratory parameters Logistic regression Lymphocyte count material Mild multivariate National neutrophil neutrophil count not differ outcome parameter parameters Patient patients Platelet Poland predictor procalcitonin Remdesivir selected Significant significant difference significantly significantly higher study population supported the disease thrombotic Tocilizumab Treatment WBCs White blood cell [DOI] 10.1016/j.advms.2022.07.003 PMC 바로가기
Efficacy of pharmacological interventions in COVID-19: A network meta-analysisCovid-19의 약리학 적 개입의 효능 : 네트워크 메타 분석Meta-Analysis Published on 2022-09-012022-09-08 Journal: British Journal of Clinical Pharmacology [Category] meta-analysis, 임상, 치료제, [키워드] 95% confidence interval Administered analysed Clinical improvement clinical recovery Controlled trial coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 database Dexamethasone drug Favipiravir followed by head Head-to-head comparison Hydroxychloroquine increase interferon Intervention investigator Lopinavir Lopinavir/ritonavir lower mortality lower risk lower risk of mortality MeSH term moderate to severe Mortality Network meta-analysis Occurrence patients with moderate pharmacological intervention Quantitative analysis Randomized controlled trial reduce reduced Relative risk Remdesivir risk Ritonavir screened Serious Adverse Event Serious Adverse Events severe COVID-19 significantly Standard of care Tocilizumab was performed [DOI] 10.1111/bcp.15338 PMC 바로가기 [Article Type] Meta-Analysis
Ultraviolet-coupled advanced oxidation processes for anti-COVID-19 drugs treatment: Degradation mechanisms, transformation products and toxicity evolutionResearch article Published on 2022-09-012022-10-05 Journal: Chemosphere [Category] 치료기술, 치료법, 치료제, [키워드] Analysis anti-COVID-19 drugs Appropriate Bacterial Combined COVID-19 Degradation degradation mechanism Dexamethasone drug Evolution functional H2O2 HCQ Hydroxychloroquine Intermediates analysis investigated Luminescence Luminescent bacterial test mechanisms parameter pathway Pneumonia positive predicted RDV Remdesivir risk significantly higher Toxicity Treatment UV/AOPs viruses [DOI] 10.1016/j.chemosphere.2022.134968 [Article Type] Research article
Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study코로나바이러스 질병 2019(COVID-19) 환자 치료를 위한 렘데시비르 플러스 덱사메타손 대 덱사메타손 단독 요법: 보충 O2 요법이 필요한 환자: 전향적 통제된 비무작위 연구Controlled Clinical Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, 치료제, [키워드] 30-Day mortality Antiviral baseline calculated clinical outcomes cohorts Combination Controlled coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CRP D-dimer Dexamethasone drug effective Endpoint enrolled evaluate evaluated faster fibrinogen FiO2 group groups Hospitalization IMPROVE independent Inflammatory inflammatory markers Kaplan-Meier Kaplan-Meier curve Kaplan-Meier curves laboratory characteristics log-rank test median Mortality neutrophil neutrophil/lymphocyte ratio no differences occurred primary endpoint primary endpoints Prospective reducing mortality reduction in reduction in mortality Remdesivir Respiratory failure Respiratory function Sample size SARS-CoV-2 clearance secondary Secondary endpoints shown significant difference significant differences survival the log-rank test therapy treat Treatment viral clearance were used [DOI] 10.1093/cid/ciac014 PMC 바로가기 [Article Type] Controlled Clinical Trial